leadf
logo-loader
viewImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies says subsidiary Talem Therapeutics enters research license agreement with Janssen Research & Development

Ilse Roodink, chairwoman of Talem's Scientific Advisory Committee and Scientific Director at ImmunoPrecise Antibodies  Europe said: "This Agreement validates Talem's business concept in early antibody discovery and development”

Antibodies
Talem Therapeutics is focused on the discovery and development of therapeutic antibodies targeting emerging, infectious diseases, neurology, immuno-oncology, inflammation, and rare/ specialty diseases

ImmunoPrecise Antibodies Ltd. (CVE:IPA) (OTCQB:IPATF) said its subsidiary Talem Therapeutics has entered into a research license agreement with Janssen Research & Development, LLC providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target.

Under the agreement, ImmunoPrecise  - a global leader in therapeutic antibody discovery and development – said Janssen holds an option to acquire all commercial rights to the antibodies. The financial details of the transaction have not been disclosed.

READ: ImmunoPrecise Antibodies and its AI collaborator team up on research program to help fight coronavirus

Ilse Roodink, chairwoman of Talem's Scientific Advisory Committee and Scientific Director at ImmunoPrecise Antibodies  Europe said: "This Agreement validates Talem's business concept in early antibody discovery and development.”

She added: "It is a significant milestone to see this exclusive agreement through Talem finalized with Janssen, a company so well positioned to further develop and maximize the potential of these lead candidates for clinical applications."

Talem Therapeutics is focused on the discovery and development of therapeutic antibodies targeting emerging, infectious diseases, neurology, immuno-oncology, inflammation, and rare/ specialty diseases.

Jennifer Bath, president and CEO of ImmunoPrecise Antibodies added: "Talem continues to build a therapeutic program pipeline for commercial partnering, thus optimizing shareholder value creation based on IPA's infrastructure across Europe and North America."

ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients.

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 2.33 CAD

TSX-V:IPA
Market: TSX-V
Market Cap: $162.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmunoPrecise Antibodies on an aggressive sales and business development drive

ImmunoPrecise Antibodies Ltd's (CVE:IPA) president and chief executive Jennifer Bath caught up with Proactive Investors at the Spring Investor Summit 2019 in New York City. Operating from their laboratory facilities at the Vancouver Island Technology Park in Victoria, British Columbia...

on 2/4/19

2 min read